II. Indications
III. Contraindications
IV. Dosing
- See Monoclonal Antibody for preparation for use
- Dosing
- Start: 400 mg SQ every other week at weeks 0, 2 and 4
- Next: 400 mg SQ every 4 weeks
- Background
- Injection sites include thigh and Abdomen (rotate injection sites)
- Divide 400 mg dose into 2 separate injection sites
- Available as a Preloaded syringe
- Refrigerate and protect from light
- Allow to warm to room Temperature for 15 to 30 minutes before injection (decreased pain)
- Injection sites include thigh and Abdomen (rotate injection sites)
V. Mechanism
- See Tumor Necrosis Factor Inhibitor
- Monoclonal Antibody against human Tumor Necrosis Factor alpha
VI. Precautions
- See TNF Inhibitor
- TNF Inhibitors predispose to serious infections and malignancy
- Prepare for TNF Inhibitor use with infection screening (e.g. Tuberculosis) and Immunizations
VII. Adverse Effects
- See Tumor Necrosis Factor Inhibitor
- Mild to moderate Injection site reactions (<10% of patients)
VIII. Safety
- Considered safe in Lactation
- Pregnancy
- May use in pregnancy (any trimester) if indicated and benefit outweighs risk
- Fetal exposure risk does NOT appear to increase after 20 weeks (unlike other TNF Inhibitors)
IX. Resources
- Certolizumab Injection Kit (DailyMed)
X. References
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
- (2023) Biologics for Crohn's Disease, Presc Lett, #390826
- (2023) Drugs for Inflammatory Bowel Disease, Med Lett Drug Ther 65: 105-12
Images: Related links to external sites (from Bing)
Related Studies
cimzia (on 3/23/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
CIMZIA 2X200 MG/ML SYRINGE KIT | $4,944.14 each |
Ontology: certolizumab pegol (C1872109)
Definition (NCI) | A Fab fragment of a recombinant, humanized monoclonal antibody directed against the proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) and conjugated to polyethylene glycol (PEG), with anti-inflammatory activity. Upon administration, certolizumab binds to TNF-alpha and prevents the interaction of this cytokine with endogenous cell surface receptors, thereby rendering TNF-alpha inactive and inhibiting TNF-mediated inflammatory responses. TNF-alpha is a protein involved in inflammation, cell survival, and apoptosis. Pegylation of certolizumab allows for an improved pharmacokinetic profile. |
Definition (NCI) | A Fab fragment of a recombinant, humanized monoclonal antibody directed against the proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha), with anti-inflammatory activity. Upon administration, certolizumab binds to TNF-alpha, preventing the interaction of this cytokine with endogenous cell surface receptors, thereby rendering TNF-alpha inactive and inhibiting TNF-mediated inflammatory responses. TNF-alpha is a protein involved in inflammation, cell survival, and apoptosis. |
Concepts | Pharmacologic Substance (T121) , Amino Acid, Peptide, or Protein (T116) , Immunologic Factor (T129) |
MSH | C468008 |
SnomedCT | 430306004, 430307008 |
English | Certolizumab pegol, Certolizumab pegol (product), Certolizumab pegol (substance), certolizumab, CERTOLIZUMAB, certolizumab pegol (medication), CERTOLIZUMAB PEGOL, Certolizumab Pegol, CZP, Certolizumab, certolizumab pegol |
Spanish | certolizumab pegol (producto), certolizumab pegol (sustancia), certolizumab pegol |
Ontology: Cimzia (C2343521)
Concepts | Immunologic Factor (T129) , Pharmacologic Substance (T121) |
MSH | C468008 |
English | Cimzia, UCB Pharma brand of certolizumab pegol |